Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 527-534

  Santander Ballestín, Sonia ^a   Cebrián, Carmelo ^b   Esquivias, Paula ^b   Conde, Blanca ^a   Esteva, Francisco ^a,b   Jiménez, Pilar ^b   Ortego, Javier ^a,b   Lanas, Ángel ^a,b   Piazuelo, Elena ^a,b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Cyclooxygenase; EP receptors; Esophageal adenocarcinoma; Nude mice; Xenograft

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CYCLOOXYGENASE 2; INDOMETACIN; MESSENGER RNA; PARECOXIB; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION; XENOGRAFT;

ADENOCARCINOMA; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; INDOMETHACIN; ISOXAZOLES; MALE; MICE; MICE, NUDE; RANDOM ALLOCATION; RECEPTORS, PROSTAGLANDIN E; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855672834     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1219     Document Type: Article

References (49)

1. Brown LM, Devesa SS and Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100: 1184-1187, 2008.
2. Botterweck AA, Schouten LJ, Volovics A, et al: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29: 945-954, 2000.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics. Cancer J Clin 55: 74-108, 2005.
4. Vaughan TL, Dong LM, Blount PL, et al: Non-steroidal antiinflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6: 945-952, 2005. (Pubitemid 41685227)
5. Corley DA, Kerlikowske K, Verma R and Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47-56, 2003. (Pubitemid 36055338)
6. Piazuelo E, Jimenez P and Lanas A: COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 9: 2267-2280, 2003. (Pubitemid 37139099)
7. Li Z, Shimada Y, Kawabe A, et al: Suppression of N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 22: 547-551, 2001. (Pubitemid 32288653)
8. Buttar NS, Wang KK, Leontovich O, et al: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112, 2002. (Pubitemid 34267291)
9. Miwa K, Sahara H, Segawa M, et al: Reflux of duodenal or gastroduodenal contents induces esophageal carcinomas in rats. Int J Cancer 67: 269-274, 1996. (Pubitemid 26274160)
10. Oyama K, Fujimura T, Ninomiya I, et al: A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 26: 565-570, 2005. (Pubitemid 41214145)
11. Jiménez P, Piazuelo E, Cebrian C, et al: Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 31: 440-451, 2010.
12. Jacobson GA, Narkowicz C, Lord R, Howard BJ and Chung S: Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus. Dis Esophagus 20: 265-268, 2007. (Pubitemid 46831261)
13. Li Y, Wo JM, Ray MB, et al: Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. World J Gastroenterol 12: 928-934, 2006.
14. Kuramochi H, Vallbohmer D, Uchida K, et al: Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg 8: 1007-1016, 2004.
15. Morris CD, Armstrong GR, Bigley G, et al: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96: 990-996, 2001. (Pubitemid 32319127)
16. Zimmermann KC, Sarbia M, Weber AA, et al: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999. (Pubitemid 29062978)
17. Wilson KT, Fu S, Ramanujam KS and Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929-2934, 1998. (Pubitemid 28335064)
18. Buskens CJ, Van Rees BP, Sivula A, et al: Prognostic significance of elevate cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122: 1800-1807, 2002. (Pubitemid 34651424)
19. Breyer RM, Emeson RB, Breyer MD, et al: Alternative splicing generates multiple isoforms of a rabbit prostaglandin E2 receptor. J Biol Chem 269: 6163-6169, 1994. (Pubitemid 24243005)
20. Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: structures, properties and functions. Physiol Rev 79: 1193-1226, 1999. (Pubitemid 29473315)
21. Båtshake B, Nilsson C and Sundelin J: Molecular characterization of the mouse prostanoid EP1 receptor gene. Eur J Biochem 231: 809-814, 1995.
22. Abramovitz M, Adam M, Boie Y, et al: Human prostanoid receptors: cloning and characterization. Prostaglandin Thromboxane Leukot Res 23: 499-504, 1995.
23. Regan JW: EP2 and EP4 prostanoid receptor signaling. Life Sci 74: 143-153, 2003.
24. Hull MA, Ko SC and Hawcroft G: Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3: 1031-1039, 2004. (Pubitemid 39199598)
25. Bastien L, Sawyer N, Grygorczyk R, Metters KM and Adam M: Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem 269: 11873-11877, 1994. (Pubitemid 24196675)
26. George RJ, Sturmoski MA, Anant S and Houchen CW: EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83: 112-120, 2007. (Pubitemid 46149405)
27. Watanabe K, Kawamori T, Nakatsugi S, et al: Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 156: 57-61, 2000. (Pubitemid 30326768)
28. Sonoshita M, Takaku K, Sasaki N, et al: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7: 1048-1051, 2001. (Pubitemid 32937386)
29. Niho N, Mutoh M, Kitamura T, et al: Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 96: 260-264, 2005. (Pubitemid 40895073)
30. Piazuelo E, Jiménez P, Strunk M, Santander S, et al: Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat 81: 150-161, 2006. (Pubitemid 44666498)
31. Tuynman JB, Buskens CJ, Kemper K, et al: Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242: 840-849, 2005.
32. Sawaoka H, Kawano S, Tsuji S, et al: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-G1067, 1998.
33. Britain RT, Boutal L, Carter MC, et al: AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation 72: 1208-1218, 1985. (Pubitemid 16126800)
34. Rockett JC, Larkin K, Darnton SJ, Morris AG and Matthews HR: Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 75: 258-263, 1997. (Pubitemid 27019571)
35. Van Hattum AH, Pinedo HM, Schluper HM, Hausheer SH and Boven E: New highly lipophilic camptothecin BNP 1350 is an effective drug in experimental human cancer. Int J Cancer 88: 260-266, 2000.
36. Jansen WJ, Kolfschoten GM, Erkelens CA, van Ark-Otte J, Pinedo HM and Boven E: Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int J Cancer 73: 891-896, 1997. (Pubitemid 127483047)
37. Powell WS: Reversed-phase high-pressure liquid chromatography of araquidonic acid metabolites formed by cyclooxygenase and lipoxygenase. Anal Biochem 154: 332-337, 1986.
38. Morton CL and Houghton PJ: Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2: 247-250, 2007. (Pubitemid 47040037)
39. Fidler IJ: New developments in in vivo models of neoplasia. Cancer Metastasis Rev 10: 191-192, 1991.
40. Eccles SA, Box G, Court W, Sandle J and Dean CJ: Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 24-25: 279-291, 1994.
41. Hoffman RM: Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem 56: 1-3, 1994.
42. Padi SS, Jain NK, Singh S and Kulkarni SK: Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol 491: 69-76, 2004. (Pubitemid 38501777)
43. Talley JJ, Bertenshaw SR, Brown DL, et al: N-[[(5-methyl-3- phenylisoxazol-4-yl) phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43: 1661-1663, 2000. (Pubitemid 30304998)
44. O'Donghue GT, Roche-Nagel G, Harmey JH and Bouchier-Hayes DJ: Cyclooxygenase-2 inhibition attenuates surgically induced residual tumor growth and metastases following cytoreductive surgery in a murine model of breast cancer. J Surg Res 114: 227, 2003.
45. Smakman N, Kranenburg O, Vogten JM, Bloemendaal AL, van Diest P and Borel Rinkes IH: Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res 11: 41-48, 2005. (Pubitemid 40075776)
46. Klein WA, Miller HH, Anderson M and De Cosse JJ: The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60: 2863-2868, 1987. (Pubitemid 18005855)
47. Zhang X, Morham SG, Langenbach R and Young DA: Malignant transformation and antineoplastic actions of non-steroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451-459, 1999. (Pubitemid 29395373)
48. Chiu CH, McEntee MF and Whelan J: Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57: 4267-4273, 1997. (Pubitemid 27413435)
49. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.